Aqueous vs Alcohol Chlorhexidine Skin Preparation for Prevention of Cesarean Section Wound Infections

November 27, 2023 updated by: Yaneve Fonge

A Randomized Control Trial of Chlorhexidine Gluconate Aqueous Solution vs Chlorhexidine Gluconate With Isopropyl Alcohol Skin Preparations for Prevention of Cesarean Section Wound Infections

This will be a single-center randomized control trial comparing the efficacy of two different formulations of Chlorhexidine surgical skin preparation in preventing cesarean section wound infections. Participants will be randomized to either 4% Chlorhexidine Gluconate aqueous solution (CHG) or 2% Chlorhexidine with isopropyl alcohol (CHG-IPA) 70% to examine the risk of infectious morbidity in those undergoing cesarean delivery. There will also be a cost-effectiveness analysis of the two preoperative skin preparations.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

1470

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15260
        • Recruiting
        • University of Pittsburgh
        • Contact:
          • Yaneve N Fonge

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Women undergoing cesarean delivery at Magee Women's Hospital

Exclusion Criteria:

  • Inability to obtain consent (language barrier, emergency cesarean section etc.)
  • Allergy to chlorhexidine or alcohol
  • Chorioamnionitis
  • Emergency cesareans where cannot wait for chlorhexidine alcohol to dry
  • bowel injury at time of cesarean section
  • Women who are delivered at another institution and are transferred postpartum to Magees Women's Hospital

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 2% Chlorhexidine gluconate with 70% alcohol (ChloraPrep)
Including cases undergoing elective &non elective caesarean section. Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
Other Names:
  • ChloraPrep
Experimental: 4% chlorhexidine gluconate (Hibiclens)
Including cases undergoing elective & nonelective caesarean section. Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
Other Names:
  • Hibiclens

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants with Surgical site Infection
Time Frame: Within 30 days post cesarean
Superficial or deep surgical-site infection within 30 days after cesarean delivery, on the basis of the National Healthcare Safety Network definitions of the Centers for Disease Control and Prevention.
Within 30 days post cesarean

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Endometritis
Time Frame: Within 30 days post cesarean
Within 30 days post cesarean
Number of participants with seroma
Time Frame: Within 30 days post cesarean
Within 30 days post cesarean
Number of Participants With Skin Irritation
Time Frame: within 48 hours from delivery
within 48 hours from delivery
Number of Participants With Allergic Reaction
Time Frame: within 48 hours from delivery
within 48 hours from delivery
Number of Participants with intrabdominal/pelvic abscess
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of Participants with necrotizing fasciitis
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of Participants with sepsis
Time Frame: Within 90 days post cesarean
With wound/uterine infection as the source
Within 90 days post cesarean
Length of Hospital Stay
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of Participants With Re-admissions or Office Visits for Wound-related Problems
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of Participants with ICU admission for wound infectious complications
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of Participants with Need for wound opening, exploration, or washout in the operating room
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of Participants who needed wound vacuum
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of Participants who needed home health
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of patients who needed antibiotics
Time Frame: Within 90 days post cesarean
will also collect route of antibiotic administration and duration of treatment to assist with cost analysis
Within 90 days post cesarean
Number of doses of antibiotic treatment
Time Frame: Within 90 days post cesarean
for wound infection complications
Within 90 days post cesarean
Antibiotic regimens (medication names) used to treat infection
Time Frame: Within 90 days post cesarean
for wound infection complications
Within 90 days post cesarean
Number of participants with positive culture from wound
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
The type of bacterial species isolated from wound infection cultures
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Number of participants with hematoma
Time Frame: Within 90 days post cesarean
Within 90 days post cesarean
Cost Savings
Time Frame: Within 90 days post cesarean
costs (dollars) associated with a hospital stay, office visits and re-admissions for infection-related complications, ICU admission for infectious complications, wound exploration or washout in the operating room, wound vacuum use, home health, antibiotic prescriptions, and duration of treatment will be collected and used to calculate the cost of wound infection management. The cost difference between groups will be calculated to estimate cost savings.
Within 90 days post cesarean

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Yaneve Fonge, MD, University of Pittsburgh

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 9, 2023

Primary Completion (Estimated)

October 31, 2024

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

June 7, 2023

First Submitted That Met QC Criteria

June 15, 2023

First Posted (Actual)

June 27, 2023

Study Record Updates

Last Update Posted (Actual)

November 29, 2023

Last Update Submitted That Met QC Criteria

November 27, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surgical Site Infection

Clinical Trials on 2% Chlorhexidine gluconate with 70% alcohol

3
Subscribe